# HCA Healthcare Moat

Status: published. Policy: company-analysis-1.

HCA has an established hospital footprint, centralized purchasing and operating services, and some regulatory protection against entry. The passages do not demonstrate relative cost savings, local market dominance, patient dependency or durable payer bargaining power sufficient to establish a moat. Pricing freedom is constrained by government reimbursement and negotiated insurer contracts. Growing revenues and sustained profits demonstrate operating capability, but do not isolate realized price increases or establish competitive insulation.

## cost_advantage

National supply contracts and shared operating services are current capabilities that could spread purchasing and administrative costs across HCA's hospital footprint. A comparative cost advantage is not demonstrated.

Durability: The infrastructure was already operating at year-end 2025, but the passages provide neither quantified savings nor evidence that competitors cannot replicate it.

Risks: Labor competition, continuing capital requirements and outpatient substitution could offset scale benefits. Consolidated profitability cannot establish lower costs than competitors.

Invalidation: The cost-advantage hypothesis would be invalidated by comparable purchasing and administrative costs at smaller providers, or sustained increases in HCA's comparable cost per service without offsetting clinical or operating benefits.

Competitors: Not established
## intangible_assets

Existing facilities in states with certificate-of-need requirements have potential regulatory entry protection. The passages establish exposure to these restrictions, but not their materiality or an HCA-specific competitive advantage.

Durability: Protection depends on state law and approval practices. Neither the proportion of protected earnings nor the persistence of effective entry restrictions is established.

Risks: Removal of approval requirements, competing outpatient providers and restrictions on HCA's own expansion can weaken the benefit.

Invalidation: The regulatory-protection hypothesis would be invalidated if material service areas repeal or routinely waive entry restrictions and new capacity enters without meaningful approval barriers.

Competitors: Not established
- [https://www.sec.gov/Archives/edgar/data/860730/000119312526044769/hca-20251231.htm](https://www.sec.gov/Archives/edgar/data/860730/000119312526044769/hca-20251231.htm) · 2026-02-10
- [https://www.sec.gov/Archives/edgar/data/860730/000119312526321077/hca-20260630.htm](https://www.sec.gov/Archives/edgar/data/860730/000119312526321077/hca-20260630.htm) · 2026-07-28
- [https://www.sec.gov/Archives/edgar/data/860730/000119312526106142/d939252ddef14a.htm](https://www.sec.gov/Archives/edgar/data/860730/000119312526106142/d939252ddef14a.htm) · 2026-03-13
- [https://www.sec.gov/Archives/edgar/data/860730/000095017025020134/hca-20241231.htm](https://www.sec.gov/Archives/edgar/data/860730/000095017025020134/hca-20241231.htm) · 2025-02-14
- [https://www.sec.gov/Archives/edgar/data/860730/000095017024016524/hca-20231231.htm](https://www.sec.gov/Archives/edgar/data/860730/000095017024016524/hca-20231231.htm) · 2024-02-16
- [https://www.sec.gov/Archives/edgar/data/860730/000119312526191444/hca-20260331.htm](https://www.sec.gov/Archives/edgar/data/860730/000119312526191444/hca-20260331.htm) · 2026-04-29

[JSON](https://beanvest.com/stock/hca/moat.json)